Adjuvant Chemotherapy of Superficial Transitional Cell Bladder Carcinoma:Preliminary Results of a European Organization for Research onTreatment of Cancer Randomized Trial Comparing Doxorubicin Hydrochloride, Ethoglucid and Transurethral Resection Alone

Abstract

Patients with superficial transitional cell carcinoma of the bladder were entered in a randomized clinical trial to compare the efficacies of transurethral resection alone or followed by bladder instillation of doxorubicin hydrochloride or ethoglucid (Epodyl) for 1 year. Results showed that adjuvant chemotherapy with the selected drugs prolonged the mean interval between recurrences. Mild systemic toxicity and chemical cystitis were observed in 3 and 3 per cent, respectively, of the patients given ethoglucid, and in 5 and 4 per cent, respectively, of those taking doxorubicin.

Factors Affecting Survival in Primary Superficial Bladder Cancer

“…There fore these two parameters should be described by the pathologist. Besides these factors, multiplicity does not seem to be such an important factor as Dalesio et al [5] and Kurth et al [ 14] have reported. In both studies the Cox model was used and multiplicity was defined as the most important single factor [5,14],…”

Effects of Intravesical Mitomycin and Distilled Water on Recurrence After TUR-TM in Ta, T1 Tumors

“…Düşük risk grubundaki hastalarda tedavi kolları arasında nüks gelişimi açısından istatistiksel anlamlı fark bulunamamıştır. Tek, primer KIOMK'lar ilk nüks zamanı ve nüks oranı ile değerlendirildiğinde düşük risk grubundadır [16,17]. Multiple tümörler ise nüks açısından yüksek riske sahip olup, tekrarlayan intravezikal ilaç uygulamaları ile tedavi edilir.…”

“…İki grubu benzer tedavi programına tabi tutmak, düşük riskli grupta fazladan tedavi anlamına gelebilir [18]. Diğer taraftan, düşük risk grubunda adjuvan kemoterapinin yalnızca TUR-Tm ile karşılaştırıldığında, nüksü anlamlı oranda azalttığı genel kabul görmüştür [17]. Bütün bunlar göz önünde bulundurulduğunda, düşük riskli hasta grubunda TUR-Tm sonrası adjuvan tedavide DS uygulanmasının mantıklı bir yaklaşım olduğu düşünülebilir.…”

Long-term prophylactic effects of intravesical instillation of thiotepa and oral administration of UFT on the recurrence of superficial bladder cancer after transurethral resection

“…Many reports have demonstrated the effectiveness of intravesical instillation of anti-cancer agents. [5][6][7][8] We have also reported the results of our studies conducted to examine the effects of various anticancer agents in preventing the postoperative recurrence of superficial bladder cancer. 9,10 In the present study, we analyzed the long-term effects of two chemotherapeutic agents, thiotepa, as an intravesical prophylactic treatment, and UFT, a 4 : 1 mixture of uracil and tegafur (a 5-fluorouracil pro-drug), for chemoprevention, in preventing the postoperative recurrence of superficial bladder cancer.…”